Veena Meena1, Charu Lata Bansal2. 1. Department of Obstetrics and Gynaecology, Smt. Sucheta Kriplani Hospital and Kalawati Saran Children's Hospital, Lady Hardinge Medical College, New Delhi, India. 2. Department of Obstetrics and Gynaecology, Gangori Hospital, SMS Medical College, Jaipur, Rajasthan India.
Abstract
INTRODUCTION:Vaginal discharge is a commonest complaint among women in reproductive age group. Infective vaginal discharge can be broadly categorized into vaginitis or mucopurulent cervicitis. Vaginitis is predominantly caused by bacterial vaginosis, vaginal candidiasis, vaginal trichomoniasis, etc. Mucopurulent cervicitis is due to chlamydia or gonococcal infection. The targeted management is based on identification of causative organism and targeting the therapy against it, while syndromic management is based on high risk factors's presence. AIMS AND OBJECTIVES: To study the effect of targeted management as compared to syndromic management in achieving a complete cure for abnormal vaginal discharge and to study the microbial flora of women presenting with abnormal vaginal discharge. METHOD: The study is a randomized control trial conducted at tertiary health care on 200 women who presented with abnormal vaginal discharge, distributed in two groups A and B each consisted of 100 women. Group A underwent laboratory investigations, and treatment was started as soon as reports were available. Group B was given syndromic management based on high risk factors's presence. Both groups were followed up after 2 weeks. RESULTS: The prevalence of various organisms in vaginal discharge was candidiasis 39 %, bacterial vaginosis 28 %, trichomoniasis 5 %, N. gonorrhoeae 5 % and chlamydia 2 % among the 100 women in group A. Response to treatment for vaginitis was 76.3 % in group A, whereas it was 41 % in group B. With cervicitis, 71.4 % women responded to treatment in targeted group as compared to 54 % in syndromic management group. CONCLUSION: There is a potential disadvantage of syndromic management because of its total reliability on a subjective clinical assessment.
RCT Entities:
INTRODUCTION: Vaginal discharge is a commonest complaint among women in reproductive age group. Infective vaginal discharge can be broadly categorized into vaginitis or mucopurulent cervicitis. Vaginitis is predominantly caused by bacterial vaginosis, vaginal candidiasis, vaginal trichomoniasis, etc. Mucopurulent cervicitis is due to chlamydia or gonococcal infection. The targeted management is based on identification of causative organism and targeting the therapy against it, while syndromic management is based on high risk factors's presence. AIMS AND OBJECTIVES: To study the effect of targeted management as compared to syndromic management in achieving a complete cure for abnormal vaginal discharge and to study the microbial flora of women presenting with abnormal vaginal discharge. METHOD: The study is a randomized control trial conducted at tertiary health care on 200 women who presented with abnormal vaginal discharge, distributed in two groups A and B each consisted of 100 women. Group A underwent laboratory investigations, and treatment was started as soon as reports were available. Group B was given syndromic management based on high risk factors's presence. Both groups were followed up after 2 weeks. RESULTS: The prevalence of various organisms in vaginal discharge was candidiasis 39 %, bacterial vaginosis 28 %, trichomoniasis 5 %, N. gonorrhoeae 5 % and chlamydia 2 % among the 100 women in group A. Response to treatment for vaginitis was 76.3 % in group A, whereas it was 41 % in group B. With cervicitis, 71.4 % women responded to treatment in targeted group as compared to 54 % in syndromic management group. CONCLUSION: There is a potential disadvantage of syndromic management because of its total reliability on a subjective clinical assessment.
Authors: F Moherdaui; B Vuylsteke; L F Siqueira; M Q dos Santos Júnior; M L Jardim; A M de Brito; M C de Souza; D Willers; J C Sardinha; A S Benzaken; M C Ramos; H Bueno; L G Rodrigues; P J Chequer Journal: Sex Transm Infect Date: 1998-06 Impact factor: 3.519
Authors: C A Ryan; A Zidouh; L E Manhart; R Selka; M Xia; M Moloney-Kitts; J Mahjour; M Krone; B N Courtois; G Dallabetta; K K Holmes Journal: Sex Transm Infect Date: 1998-06 Impact factor: 3.519
Authors: S E Sánchez; L A Koutsky; J Sánchez; A Fernández; J Casquero; J Kreiss; M Catlin; M Xia; K K Holmes Journal: Sex Transm Infect Date: 1998-06 Impact factor: 3.519